Publications by authors named "Michel Dib"

16Publications

Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Mol Diagn Ther 2009 ;13(2):115-25

Assistance Publique - Hôpitaux de Paris, Fédération des Maladies du Système Nerveux, Centre Référent Maladie Rare SLA, Hôpital de la Pitié-Salpêtrière, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF03256320DOI Listing
October 2009

Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:
Michel Dib

Ther Clin Risk Manag 2008 Oct;4(5):1061-78

Fédération du système nerveux central, Hôpital de la Salpêtrière, Assistance Publique- Hôpitaux de Paris, France.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621398PMC
http://dx.doi.org/10.2147/tcrm.s3983DOI Listing
October 2008

Issues for clinical drug development in neurodegenerative diseases.

Authors:
Michel Dib

Drugs 2005 ;65(17):2463-79

Service de Neurologie, Hôpital de la Salpêtrière, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-200565170-00004DOI Listing
February 2006

Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome.

Prog Neuropsychopharmacol Biol Psychiatry 2006 Jan 21;30(1):131-7. Epub 2005 Oct 21.

Unité Clinique de Psychiatrie Biologique, Bron, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pnpbp.2005.08.015DOI Listing
January 2006

Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome.

Hum Psychopharmacol 2005 Oct;20(7):511-9

Service de Psychiatrie, Hôpital d'Instruction des Armées Percy, Clamart, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hup.718DOI Listing
October 2005

Neuroprotective effect of riluzole in acute noise-induced hearing loss.

Neuroreport 2005 Jul;16(10):1087-90

Inserm U 583 et Université Montpellier 1- Hôpital Saint Eloi, 34090 Montpellier Cedex 5, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001756-200507130-00011DOI Listing
July 2005

Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression.

J Affect Disord 2003 Sep;76(1-3):191-200

Service hospitalo-Universitaire de Santé Mentale et Thérapeutique, Pr H Lôo et J-P Olié, Hôpital Sainte-Anne, 1, rue Cabanis, Paris Cedex 75674, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-0327(02)00086-1DOI Listing
September 2003

Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:
Michel Dib

Drugs 2003 ;63(3):289-310

Laboratoire Aventis, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-200363030-00004DOI Listing
April 2003

5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle.

Eur J Pharmacol 2002 Nov;454(2-3):235-9

INSERM U400, Faculté de Médecine de Créteil, 8 rue du Général Sarrail, 94010 Créteil Cédex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0014-2999(02)02489-5DOI Listing
November 2002

Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?

J Neurol 2002 Apr;249(4):367-74

Laboratoire Aventis, 46, quai de la Rapée, 75601 Paris Cedex 12, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s004150200025DOI Listing
April 2002